Amperozide

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C23H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M2W3TAG39, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but generally known as amperozide, which bears US NIH Compound Identifier 73333. Amperozide most often comes in base and hydrochloride forms. European Medicines Agency schedules Amperozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05483MIG. The term AMPEROZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). AMPEROZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amperozide under HS 29335995 and SITC 51576. As of Q4 2014, AMPEROZIDE remains the US FDA Preferred Term for this commodity. Amperozide bears US NLM identifiers UMLS ID C0051747 and NCI Concept Code C74191. SMILES: FC1CCC(C(CCCN2CCN(CC2)C(=O)NCC)C2CCC(F)CC2)CC1.